September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Iambic Ther­a­peu­tics: En­ter­ing the ‘show-me’ era for AI

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Tom Miller
  • To­tal raised $220 mil­lion
  • Head­quar­ters San Diego, CA

As two biotech rook­ies leav­ing long aca­d­e­m­ic ca­reers to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Ex­clu­sive: Af­ter dis­cov­er­ing an­tibi­otics with AI, a 31-year-old first-time CEO rais­es $17M to fight ag­ing

UK biotech bags $43M in Se­ries A to move Hunt­ing­ton's drug in­to first hu­man study

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times